Listen to this story
0:00 / 0:00
OpenAI has acquired Orchestra Bio, a startup focused on building to assist pharmaceutical companies in managing drug development workflows. The deal marks OpenAI's continued expansion into specialized enterprise verticals beyond general-purpose AI.
Orchestra Bio's technology will be integrated into OpenAI's Rosalind, the company's life sciences suite. This acquisition signals OpenAI's strategy to move beyond consumer and general business applications into highly regulated, knowledge-intensive industries where AI agents can automate complex, multi-step processes.
This is an AI-written summary. The original reporting belongs to Techmeme. How we write these · Spot a mistake?